Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deraphan
- Development stage
- Unknown
- Lead developer
- Exciva
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Deraphan (EXV-802) is a small molecule combination therapy developed by Exciva GmbH for the treatment of agitation associated with Alzheimer's disease dementia. It consists of dextromethorphan, an NMDA receptor antagonist, and EXV-801, a novel triple-acting agent that functions as a CYP2D6 inhibitor and a 5-HT2A/2C receptor inverse agonist. The inclusion of EXV-801 serves a dual purpose: it acts as a pharmacokinetic enhancer by inhibiting the metabolism of dextromethorphan to increase its systemic exposure, and it provides additional therapeutic activity through serotonin receptor modulation. This synergistic mechanism is designed to address a broad range of neuropsychiatric symptoms, including hallucinations, delusions, aggression, and agitation. The product has received Fast Track designation from the US FDA and is currently being evaluated in the Phase 2/3 SERENADA clinical trial.
- Brand names
- Deraphan
- Other names
- dextromethorphan + EXV-801
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)CYP2D6 (Cytochrome P450 2D6)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on Deraphan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Deraphan.